Roughly 2% to 4% of the world’s population has fibromyalgia, which translates to somewhere between 160 million and 320 million people. The global mean prevalence sits at about 2.7%, though rates vary dramatically depending on the country, the diagnostic criteria used, and who’s being studied.
Global Numbers by Region
Fibromyalgia exists everywhere researchers have looked for it, but not in equal proportions. The Americas report the highest average prevalence at 3.1%, followed by Europe at 2.5% and Asia at 1.7%. Within those regions, the differences between individual countries are striking.
Tunisia reports the highest known prevalence at 9.3%, followed closely by Turkey at 8.8%. The United States sits at roughly 6.4% when using broader modern diagnostic criteria. On the other end of the spectrum, Greece reports just 0.4%, Thailand 0.6%, and Denmark 0.7%. Countries like Brazil (2.5%), Spain (2.3% to 2.4%), Germany (2.1% to 3.2%), and Portugal (3.6%) fall in the middle range. In Asia, Bangladesh reports 3.6% while China comes in at 0.8% and Malaysia at 0.9%.
These gaps partly reflect real differences in population health, but they also reflect how aggressively clinicians screen for fibromyalgia and which diagnostic standards a given country follows. In places where awareness is low or where widespread pain is attributed to other causes, rates look artificially small.
Women Are Diagnosed Far More Often
Fibromyalgia is overwhelmingly diagnosed in women. Depending on the study, women account for 80% to 90% of cases. UK primary care data shows this ratio has actually become more lopsided over time: in the period from 2004 to 2008, about 85% of new diagnoses were women, and by 2014 to 2018 that figure had risen to over 90%.
Whether this reflects a genuine biological difference or a diagnostic blind spot is debated. Some studies using population surveys rather than clinic records find a less dramatic split, with women making up closer to 59% of cases. Men with fibromyalgia tend to delay seeking medical help, and clinicians may be less likely to consider fibromyalgia in male patients presenting with widespread pain. The psychosocial impact of the condition, including its effects on work, relationships, and mental health, appears similar across genders.
Age of Diagnosis
Most people receive a fibromyalgia diagnosis during middle age, and prevalence increases with age. Children and teenagers can develop fibromyalgia, but it’s uncommon. The typical patient spends years experiencing symptoms before getting a formal diagnosis, partly because the condition overlaps with so many others and partly because there’s no blood test or scan that confirms it.
Overlap With Other Conditions
Fibromyalgia frequently co-occurs with autoimmune and inflammatory diseases, which complicates both counting and treatment. Among people with lupus, pooled data from multiple studies puts the rate of co-existing fibromyalgia at about 15.8%. Similar patterns appear in rheumatoid arthritis and other chronic pain conditions. This overlap means a significant number of fibromyalgia cases are embedded within other diagnoses and may not always be counted separately in prevalence statistics.
How Diagnostic Criteria Change the Count
The number of people “with fibromyalgia” depends heavily on how the condition is defined, and those definitions have shifted several times. The original 1990 criteria required a doctor to physically press on 18 specific tender points across the body and find pain in at least 11 of them. This was time-consuming and inconsistent between clinicians.
When newer criteria were introduced in 2010, removing the tender point exam and relying instead on symptom questionnaires, diagnosis rates nearly doubled in a single year, jumping from 0.58% to 0.99% in clinical settings. Rates then stabilized around 0.80% through 2014. But a further revision in 2016 tightened requirements again, and diagnoses dropped steadily afterward, falling to just 0.27% by 2019. That’s half the rate from before the 2010 change.
This means the “real” number of people with fibromyalgia hasn’t necessarily gone up or down. What’s changed is where clinicians draw the line. Population surveys that screen everyone in a community, regardless of whether they’ve seen a doctor, consistently find higher rates than clinical records show.
The Financial Weight of Fibromyalgia
The economic burden of fibromyalgia is substantial for both individuals and healthcare systems. In the United States, estimated annual direct healthcare costs per patient range from $1,750 to $35,920, a wide spread that reflects differences in disease severity, insurance coverage, and how many specialists a person sees. Studies that include all direct costs (not just medical visits but also medications, physical therapy, and related expenses) place the average between $6,200 and $9,500 per patient per year.
These figures don’t capture lost wages, reduced work productivity, or disability payments, which often exceed the direct medical costs. For a condition affecting millions of people, the total economic impact runs into the tens of billions annually in the U.S. alone.